According to a post on the FDA’s website, Erasca’s treatment of malignant glioma was granted orphan designation.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ERAS:
- Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma
- Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline
- Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting
- Erasca Further Strengthens Business Leadership with Two Key Promotions
- Erasca Reports First Quarter 2023 Financial Results and Business Updates